Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Novel adjunctive therapies for the treatment of tuberculosis.

Ordonez AA, Maiga M, Gupta S, Weinstein EA, Bishai WR, Jain SK.

Curr Mol Med. 2014 Mar;14(3):385-95. Review.

2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
4.
5.

Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.

Prezzemolo T, Guggino G, La Manna MP, Di Liberto D, Dieli F, Caccamo N.

Front Immunol. 2014 Apr 22;5:180. doi: 10.3389/fimmu.2014.00180. eCollection 2014. Review.

6.

Inflammation and tuberculosis: host-directed therapies.

Zumla A, Rao M, Parida SK, Keshavjee S, Cassell G, Wallis R, Axelsson-Robertsson R, Doherty M, Andersson J, Maeurer M.

J Intern Med. 2015 Apr;277(4):373-87. doi: 10.1111/joim.12256. Epub 2014 May 19. Review.

7.

The resumption of consumption -- a review on tuberculosis.

Ducati RG, Ruffino-Netto A, Basso LA, Santos DS.

Mem Inst Oswaldo Cruz. 2006 Nov;101(7):697-714. Review.

8.

Managing TB in the 21st century: existing and novel drug therapies.

Guy ES, Mallampalli A.

Ther Adv Respir Dis. 2008 Dec;2(6):401-8. doi: 10.1177/1753465808099522. Review.

PMID:
19124385
9.

Prospects for advancing tuberculosis control efforts through novel therapies.

Salomon JA, Lloyd-Smith JO, Getz WM, Resch S, Sánchez MS, Porco TC, Borgdorff MW.

PLoS Med. 2006 Aug;3(8):e273.

10.
11.

Nuclear imaging: a powerful novel approach for tuberculosis.

Johnson DH, Via LE, Kim P, Laddy D, Lau CY, Weinstein EA, Jain S.

Nucl Med Biol. 2014 Nov-Dec;41(10):777-84. doi: 10.1016/j.nucmedbio.2014.08.005. Epub 2014 Aug 7. Review.

12.

Host-directed therapeutics for tuberculosis: can we harness the host?

Hawn TR, Matheson AI, Maley SN, Vandal O.

Microbiol Mol Biol Rev. 2013 Dec;77(4):608-27. doi: 10.1128/MMBR.00032-13. Review.

13.

Pediatric drug-resistant tuberculosis: a global perspective: a global perspective.

Reubenson G.

Paediatr Drugs. 2011 Dec 1;13(6):349-55. doi: 10.2165/11593160-000000000-00000. Review.

PMID:
21999648
14.

Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention.

Lin MY, Ottenhoff TH.

Endocr Metab Immune Disord Drug Targets. 2008 Mar;8(1):15-29. Review.

PMID:
18393920
15.

SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.

Poce G, Cocozza M, Consalvi S, Biava M.

Eur J Med Chem. 2014 Oct 30;86:335-51. doi: 10.1016/j.ejmech.2014.08.066. Epub 2014 Aug 27. Review.

PMID:
25173852
16.

TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Matteelli A, Carvalho AC, Dooley KE, Kritski A.

Future Microbiol. 2010 Jun;5(6):849-58. doi: 10.2217/fmb.10.50. Review.

17.

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.

Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, Schito M, Churchyard G, Swaminathan S, Hoelscher M, Zumla A.

Lancet Infect Dis. 2016 Apr;16(4):e34-46. doi: 10.1016/S1473-3099(16)00070-0. Review.

PMID:
27036358
18.

Diagnosis & treatment of tuberculosis in HIV co-infected patients.

Padmapriyadarsini C, Narendran G, Swaminathan S.

Indian J Med Res. 2011 Dec;134(6):850-65. doi: 10.4103/0971-5916.92630. Review.

19.

Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.

Ahmad S, Mokaddas E.

J Infect Public Health. 2014 Mar-Apr;7(2):75-91. doi: 10.1016/j.jiph.2013.09.001. Epub 2013 Nov 9. Review.

20.

Immunotherapy for tuberculosis: future prospects.

Abate G, Hoft DF.

Immunotargets Ther. 2016 Apr 20;5:37-45. doi: 10.2147/ITT.S81892. eCollection 2016. Review.

Supplemental Content

Support Center